Labcorp Holdings Inc.
LH Healthcare Diagnostics & Research
Labcorp Holdings Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.0 billion, up 7.25% from fiscal 2024. In the quarter to June 2026, revenue grew 5.78%, EPS grew 28.4%, free cash flow fell 42.0% and total debt rose 15.1%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for five consecutive years, revenue growth for three.
Follow LH
Labcorp Holdings Inc. (LH) EBITDA
Labcorp Holdings Inc.'s EBITDA for fiscal 2025 was $2.1B, up 19.4% from $1.7B in fiscal 2024. Over the twelve months to 30 June 2026 it was $2.2B. Over the past ten years it has ranged from $1.3B (fiscal 2023) to $3.6B (fiscal 2021); the current reading is higher than 82% of that period. Labcorp Holdings Inc. ranks 5th of 52 Diagnostics & Research companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $2.1B | 19.40% |
| FY2024 | $1.7B | 32.80% |
| FY2023 | $1.3B | (33.99%) |
| FY2022 | $2.0B | (45.56%) |
| FY2021 | $3.6B | 2.64% |
| FY2020 | $3.5B | 85.18% |
| FY2019 | $1.9B | 1.58% |
| FY2018 | $1.9B | 2.14% |
| FY2017 | $1.8B | 3.78% |
| FY2016 | $1.8B | 21.61% |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | $630.6M | 13.81% |
| Mar 2026 | $554.1M | 25.76% |
| Dec 2025 | $440.6M | (22.37%) |
| Sep 2025 | $567.6M | 0.50% |
| 42 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| DGX Quest Diagnostics Incorporated compare | $2.2B |
| LH Labcorp Holdings Inc. | $2.2B |
| IDXX IDEXX Laboratories, Inc. compare | $1.6B |
| MTD Mettler-Toledo International, Inc. compare | $1.3B |
| ILMN Illumina, Inc. compare | $1.2B |
| WAT Waters Corporation compare | $942.8M |
| RVTY Revvity Inc. compare | $775.8M |
| MEDP Medpace Holdings, Inc. compare | $611.2M |
| GH Guardant Health, Inc. compare | −$444.9M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on LH
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement